Efficacy and Safety of Imidafenacin for Overactive Bladder in Adult: a Systematic Review and Meta-analysis

Overview

Journal Int Urol Nephrol

Publisher Springer

Specialty Nephrology

Date 2015 Feb 1

PMID 25636812

Citations 6

Authors

Wei Huang

Huantao Zong

Xin Zhou

Yong Zhang

Affiliations

Soon will be listed here.

Abstract

Purpose: We carried out a systematic review and meta-analysis to assess the efficacy and safety of imidafenacin for treating overactive bladder in adult.

Methods: A literature review was performed to identify all published randomized placebo-controlled trials of imidafenacin for the treatment of OAB. The search included the following databases: MEDLINE, EMBASE. The reference lists of retrieved studies were also investigated.

Results: Five publications involving a total of 1,428 patients were used in the analysis, which compared imidafenacin with propiverine and solifenacin. We found that imidafenacin was effective in treating OAB in our meta-analysis, which was similar to propiverine in its efficacy. The mean number of UI per week (the standardized mean difference (SMD) = 1.23, 95% CI -0.19 to 2.65, p = 0.09), the mean number of urgency episodes per day (SMD = 0.26, 95% CI -0.11 to 0.63, p = 0.17), the mean number of micturitions per day (SMD = 0.01, 95% CI -0.30 to 0.31, p = 0.96), and the mean urine volume (ml) per micturition (SMD = -13.04, 95% CI -20.45 to -5.62, p = 0.0006) indicated that imidafenacin was similar to propiverine in its efficacy. Mean OABSS (SMD = 0.48, 95% CI -0.08 to 1.03, p = 0.09) indicated that imidafenacin was also similar to solifenacin in its efficacy. Besides, imidafenacin was better tolerated than propiverine in the safety, indicated by dry mouth (OR 0.73, 95% CI 0.54-0.98, p = 0.04) and any adverse events (OR 0.63, 95% CI 0.46-0.88, p = 0.006). Moreover, imidafenacin was also better tolerated than solifenacin in the safety, indicated by constipation (OR 0.21, 95% CI 0.08-0.53, p = 0.001) and any adverse events (OR 0.33, 95% CI 0.15-0.71, p = 0.004).

Conclusions: This meta-analysis indicates that imidafenacin was similar to propiverine or solifenacin in its efficacy for OAB and was better tolerated than propiverine or solifenacin in the safety for OAB. We conclude that imidafenacin is preferable to propiverine or solifenacin from a perspective of safety.

Citing Articles

Muscarinic control of cardiovascular function in humans: a review of current clinical evidence.

Palma J Clin Auton Res. 2024; 34(1):31-44.

PMID: 38305989 PMC: 10994193. DOI: 10.1007/s10286-024-01016-5.

Comparison of add-on medications for persistent storage symptoms after α-blocker treatment in BPH patients - a network meta-analysis.

Su Y, Chen H, Teoh J, Wai-Shun Chan V, Wu W, Lee H BMC Urol. 2023; 23(1):154.

PMID: 37789333 PMC: 10546657. DOI: 10.1186/s12894-023-01327-1.

Adherence to Overactive Bladder Syndrome Treatments Recent Developments and Future Perspectives.

Robinson D, OKane M, Cardozo L Int J Womens Health. 2023; 15:799-811.

PMID: 37251090 PMC: 10224686. DOI: 10.2147/IJWH.S369588.

Advances in pharmacotherapy for the treatment of overactive bladder.

Painter C, Suskind A Curr Bladder Dysfunct Rep. 2020; 14(4):377-384.

PMID: 33312325 PMC: 7732142. DOI: 10.1007/s11884-019-00562-3.

Is imidafenacin an alternative to current antimuscarinic drugs for patients with overactive bladder syndrome?.

Wu J, Peng L, Zeng X, Li H, Shen H, Luo D Int Urogynecol J. 2020; 32(5):1117-1127.

PMID: 32405660 DOI: 10.1007/s00192-020-04329-x.

References

Andersson K, Chapple C, Cardozo L, Cruz F, Hashim H, Michel M . Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol. 2009; 19(4):380-94. DOI: 10.1097/MOU.0b013e32832ce8a4. View

Murakami S, Yoshida M, Iwashita H, Otani M, Miyamae K, Masunaga K . Pharmacological effects of KRP-197 on the human isolated urinary bladder. Urol Int. 2003; 71(3):290-8. DOI: 10.1159/000072681. View

Stewart W, Van Rooyen J, Cundiff G, Abrams P, Herzog A, Corey R . Prevalence and burden of overactive bladder in the United States. World J Urol. 2003; 20(6):327-36. DOI: 10.1007/s00345-002-0301-4. View

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U . The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002; 21(2):167-78. DOI: 10.1002/nau.10052. View

Sexton C, Notte S, Maroulis C, Dmochowski R, Cardozo L, Subramanian D . Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract. 2011; 65(5):567-85. DOI: 10.1111/j.1742-1241.2010.02626.x. View

Marinkovic S, Rovner E, Moldwin R, Stanton S, Gillen L, Marinkovic C . The management of overactive bladder syndrome. BMJ. 2012; 344:e2365. DOI: 10.1136/bmj.e2365. View

Homma Y, Yamaguchi O . Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol. 2008; 15(11):986-91. DOI: 10.1111/j.1442-2042.2008.02152.x. View

Yokoyama T, Koide T, Hara R, Fukumoto K, Miyaji Y, Nagai A . Long-term safety and efficacy of two different antimuscarinics, imidafenacin and solifenacin, for treatment of overactive bladder: a prospective randomized controlled study. Urol Int. 2012; 90(2):161-7. DOI: 10.1159/000345055. View

Kobelt G, Kirchberger I, Malone-Lee J . Review. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. BJU Int. 1999; 83(6):583-90. DOI: 10.1046/j.1464-410x.1999.00004.x. View

10.

Milsom I, Abrams P, Cardozo L, Roberts R, Thuroff J, Wein A . How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001; 87(9):760-6. DOI: 10.1046/j.1464-410x.2001.02228.x. View

11.

Homma Y, Yamaguchi T, Yamaguchi O . A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol. 2008; 15(9):809-15. DOI: 10.1111/j.1442-2042.2008.02104.x. View

12.

Park C, Park J, Choo M, Kim J, Lee J, Lee J . A randomised, prospective double-blind, propiverine-controlled trial of imidafenacin in patients with overactive bladder. Int J Clin Pract. 2013; 68(2):188-96. DOI: 10.1111/ijcp.12255. View

13.

Homma Y, Yamaguchi O . A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol. 2009; 16(5):499-506. DOI: 10.1111/j.1442-2042.2009.02286.x. View

14.

Getsios D, El-Hadi W, Caro I, Caro J . Pharmacological management of overactive bladder : a systematic and critical review of published economic evaluations. Pharmacoeconomics. 2005; 23(10):995-1006. DOI: 10.2165/00019053-200523100-00003. View

15.

Abrams P, Kelleher C, Kerr L, Rogers R . Overactive bladder significantly affects quality of life. Am J Manag Care. 2001; 6(11 Suppl):S580-90. View

16.

Chapple C . Muscarinic receptor antagonists in the treatment of overactive bladder. Urology. 2000; 55(5A Suppl):33-46; discussion 50. DOI: 10.1016/s0090-4295(99)00492-6. View

17.

Zaitsu M, Mikami K, Ishida N, Takeuchi T . Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study). Adv Urol. 2011; 2011:854697. PMC: 3199201. DOI: 10.1155/2011/854697. View

18.

Wada N, Watanabe M, Kita M, Matsumoto S, Osanai H, Yamaguchi S . Effect of imidafenacin on nocturia and sleep disorder in patients with overactive bladder. Urol Int. 2012; 89(2):215-21. DOI: 10.1159/000339750. View

19.

Kobayashi F, Yageta Y, Segawa M, Matsuzawa S . Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland. Arzneimittelforschung. 2007; 57(2):92-100. DOI: 10.1055/s-0031-1296589. View

20.

Kobayashi F, Yageta Y, Yamazaki T, Wakabayashi E, Inoue M, Segawa M . Pharmacological effects of imidafenacin (KRP-197/ONO-8025), a new bladder selective anti-cholinergic agent, in rats. Comparison of effects on urinary bladder capacity and contraction, salivary secretion and performance in the Morris water maze task. Arzneimittelforschung. 2007; 57(3):147-54. DOI: 10.1055/s-0031-1296598. View